Sylvester Comprehensive Cancer Center

  • 20201130 - Alderuccio Juan

  • Investigator:
    Juan Alderuccio
    RCname Email

    Coordinator:

    IRB: 20201130

    SDG: Lymphoma
    Disease Site(s):

    Non-Hodgkin Lymphoma

    Sponsor: SCCC

    Enrolling Sites:

    Coral Springs
    Deerfield
    Gables
    Hollywood
    Plantation
    Sylvester
    UMH

    Title:

    Single-arm, open-label phase 2 study of loncastuximab tesirine in combination with rituximab in patients with advanced stage follicular lymphoma

    Eligibility Criteria - NCT04998669 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230567 - Alderuccio Juan

  • Investigator:
    Juan Alderuccio
    RCname Email

    Coordinator:

    IRB: 20230567

    SDG: Lymphoma
    Disease Site(s):

    Multiple

    Sponsor: NOVARTIS

    Enrolling Sites:

    Sylvester
    UMH

    Title:

    A phase I, open-label, multi-center study of PIT565 in patients with relapsed and/or refractory B-cell malignancies

    Eligibility Criteria - NCT05397496 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230696 - Alderuccio Juan

  • Investigator:
    Juan Alderuccio
    RCname Email

    Coordinator:

    IRB: 20230696

    SDG: Lymphoma
    Disease Site(s):

    Non-Hodgkin Lymphoma

    Sponsor: ADC THERAPEUTICS

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Hollywood
    Plantation
    Sylvester
    UMH

    Title:

    A Phase 1b Open-Label Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination with Other Anti-cancer Agents in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

    Eligibility Criteria - NCT04970901 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230724 - Alderuccio Juan

  • Investigator:
    Juan Alderuccio
    RCname Email

    Coordinator:

    IRB: 20230724

    SDG: Lymphoma
    Disease Site(s):

    Non-Hodgkin Lymphoma

    Sponsor: DANA-FARBER CANCER INSTITUTE

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Hollywood
    Plantation
    Sylvester
    UMH

    Title:

    A phase II study of glofitamab plus polatuzumab-R-CHP for patients with high-risk diffuse large B-cell lymphoma

    Eligibility Criteria - NCT05800366 *This information has been extracted from " www.clinicaltrials.gov"

  • 20231098 - Alderuccio Juan

  • Investigator:
    Juan Alderuccio
    RCname Email

    Coordinator:

    IRB: 20231098

    SDG: Lymphoma
    Disease Site(s):

    Multiple

    Sponsor: ASTRA ZENECA

    Enrolling Sites:

    Sylvester
    UMH

    Title:

    PRIMAVERA: A Modular Phase I/II, Open-label, Multicentre Study to Evaluate the Safety, Tolerability, and Efficacy of AZD3470, a PRMT5 Inhibitor, as Monotherapy and in Combination With Anticancer Agent(s) in Participants With Relapsed/Refractory Haemat

    Eligibility Criteria - NCT06137144 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210550 - Alencar Alvaro

  • Investigator:
    Alvaro Alencar
    RCname Email

    Coordinator:

    IRB: 20210550

    SDG: Lymphoma
    Disease Site(s):

    Non-Hodgkin Lymphoma

    Sponsor: Alliance

    Enrolling Sites:

    Deerfield
    Sylvester

    Title:

    Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (Nivo-MR2) Induction Followed by Lenalidomide and Nivolumab Maintenance in Primary CNS Lymphoma

    Eligibility Criteria - NCT04609046 *This information has been extracted from " www.clinicaltrials.gov"

  • 20221346 - Alencar Alvaro

  • Investigator:
    Alvaro Alencar
    RCname Email

    Coordinator:

    IRB: 20221346

    SDG: Lymphoma
    Disease Site(s):

    Non-Hodgkin Lymphoma

    Sponsor: SCCC

    Enrolling Sites:

    Sylvester

    Title:

    A phase 1/2 study of Zanubrutinib and Tafasitamab in mantle cell lymphoma

    Eligibility Criteria - NCT06029309 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230461 - Alencar Alvaro

  • Investigator:
    Alvaro Alencar
    RCname Email

    Coordinator:

    IRB: 20230461

    SDG: Lymphoma
    Disease Site(s):

    Multiple

    Sponsor: Nurix Therapeutics

    Enrolling Sites:

    Deerfield
    Gables
    Plantation
    Sylvester
    UMH

    Title:

    A Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Brutons Tyrosine Kinase (BTK) Degrader, in Adults with Relapsed/Refractory B-cell Malignancies

    Eligibility Criteria - NCT05131022 *This information has been extracted from " www.clinicaltrials.gov"

  • 20221298 - Crane Tracy

  • Investigator:
    Tracy Crane
    RCname Email

    Coordinator:

    IRB: 20221298

    SDG: Lymphoma
    Disease Site(s):

    Multiple

    Sponsor: SCCC

    Enrolling Sites:

    Aventura
    Coral Springs
    Deerfield
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester
    UMH

    Title:

    Lifestyle Intervention of Food and Exercise for Lymphoma Survivors (LIFE - L)

    Eligibility Criteria - NCT05839210 *This information has been extracted from " www.clinicaltrials.gov"

  • 20211204 - Lossos Izidore

  • Investigator:
    Izidore Lossos
    RCname Email

    Coordinator:
    RCemailImg Sara Haddadi
    RCphone +1 (305) 2433557

    IRB: 20211204

    SDG: Lymphoma
    Disease Site(s):

    Non-Hodgkin Lymphoma

    Sponsor: SCCC

    Enrolling Sites:

    Deerfield
    Gables
    Plantation
    Sylvester

    Title:

    A phase 2, open-label, study evaluating safety and efficacy of the loncastuximab in relapsed/refractory marginal zone lymphoma

    Eligibility Criteria - NCT05296070 *This information has been extracted from " www.clinicaltrials.gov"

  • 20221182 - Lossos Izidore

  • Investigator:
    Izidore Lossos
    RCname Email

    Coordinator:

    IRB: 20221182

    SDG: Lymphoma
    Disease Site(s):

    Multiple

    Sponsor: ABBVIE

    Enrolling Sites:

    Sylvester
    UMH

    Title:

    Study M22-716: A First-In-Human Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-319 in B-cell Malignancies

    Eligibility Criteria - NCT05512390 *This information has been extracted from " www.clinicaltrials.gov"

  • 20231021 - Lossos Izidore

  • Investigator:
    Izidore Lossos
    RCname Email

    Coordinator:

    IRB: 20231021

    SDG: Lymphoma
    Disease Site(s):

    Non-Hodgkin Lymphoma

    Sponsor: Hoffmann - La Roche

    Enrolling Sites:

    Deerfield
    Gables
    Plantation
    Sylvester
    UMH

    Title:

    A RANDOMIZED, OPEN-LABEL, MULTICENTER PHASE III STUDY EVALUATING EFFICACY AND SAFETY OF MOSUNETUZUMAB IN COMBINATION WITH POLATUZUMAB VEDOTIN IN COMPARISON WITH RITUXIMAB IN COMBINATION WITH GEMCITABINE PLUS OXALIPLATIN IN PARTICIPANTS WITH RELAPSED OR RE

    Eligibility Criteria - NCT05171647 *This information has been extracted from " www.clinicaltrials.gov"

  • 20190758 - Moskowitz Craig

  • Investigator:
    Craig Moskowitz
    RCname Email

    Coordinator:

    IRB: 20190758

    SDG: Lymphoma
    Disease Site(s):

    Hodgkin Lymphoma

    Sponsor: Memorial Sloan-Kettering Cancer Center

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester

    Title:

    Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma

    Eligibility Criteria - NCT03179917 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230081 - Moskowitz Craig

  • Investigator:
    Craig Moskowitz
    RCname Email

    Coordinator:

    IRB: 20230081

    SDG: Lymphoma
    Disease Site(s):

    Hodgkin Lymphoma

    Sponsor: SCCC

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester
    UMH

    Title:

    A randomised phase III trial with a PET response adapted design comparing ABVD +/- ISRT with A2VD +/- ISRT in patients with previously untreated stage IA/IIA Hodgkin lymphoma

    Eligibility Criteria - NCT04685616 *This information has been extracted from " www.clinicaltrials.gov"

  • 20231251 - Moskowitz Craig

  • Investigator:
    Craig Moskowitz
    RCname Email

    Coordinator:

    IRB: 20231251

    SDG: Lymphoma
    Disease Site(s):

    Multiple

    Sponsor: Seagen Inc

    Enrolling Sites:

    Sylvester
    UMH

    Title:

    An open-label phase 1 study to evaluate the safety of SGN-35T in adults with advanced malignancies

    Eligibility Criteria - NCT04947319 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230797 - Pongas Georgios

  • Investigator:
    Georgios Pongas
    RCname Email

    Coordinator:

    IRB: 20230797

    SDG: Lymphoma
    Disease Site(s):

    Non-Hodgkin Lymphoma

    Sponsor: BEIGENE

    Enrolling Sites:

    Deerfield
    Gables
    Hollywood
    Plantation
    Sylvester

    Title:

    An Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of BCL2 Inhibitor BGB-11417 in Patients With Relapsed/Refractory Waldenstrm's Macroglobulinemia

    Eligibility Criteria - NCT05952037 *This information has been extracted from " www.clinicaltrials.gov"

  • AMC-101 - Ramos, Juan Carlos

  • Investigator:
    Juan Carlos Ramos
    RCname Email

    Coordinator:

    IRB: 20180056

    SDG: Lymphoma
    Disease Site(s):

    Non-Hodgkin Lymphoma

    Sponsor: AMC

    Enrolling Sites:

    JMH
    Sylvester
    UMH

    Title:

    AMC-101: A Pilot Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas A Trial of the AIDS Malignancy Consortium (AMC)

    Eligibility Criteria - NCT03220022 *This information has been extracted from " www.clinicaltrials.gov"

  • 20231198 - Ramos Juan Carlos

  • Investigator:
    Juan Carlos Ramos
    RCname Email

    Coordinator:

    IRB: 20231198

    SDG: Lymphoma
    Disease Site(s):

    Multiple

    Sponsor: AMC

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 2 Trial of Ixazomib for Kaposi Sarcoma

    Eligibility Criteria - NCT04305691 *This information has been extracted from " www.clinicaltrials.gov"

  • 20220155 - Schatz Jonathan

  • Investigator:
    Jonathan Schatz
    RCname Email

    Coordinator:

    IRB: 20220155

    SDG: Lymphoma
    Disease Site(s):

    Non-Hodgkin Lymphoma

    Sponsor: Alliance

    Enrolling Sites:

    Aventura
    Coral Springs
    Deerfield
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester

    Title:

    A RANDOMIZED PHASE II STUDY OF CHO(E)P VS CC-486-CHO(E)P VS DUVELISIB-CHO(E)P IN PREVIOUSLY UNTREATED CD30 NEGATIVE PERIPHERAL T-CELL LYMPHOMAS

    Eligibility Criteria - NCT04803201 *This information has been extracted from " www.clinicaltrials.gov"

  • 20221326 - Schatz Jonathan

  • Investigator:
    Jonathan Schatz
    RCname Email

    Coordinator:

    IRB: 20221326

    SDG: Lymphoma
    Disease Site(s):

    Mycosis Fungoides

    Sponsor: ETCTN

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester

    Title:

    A phase I study with an expansion cohort of duvelisib and nivolumab in mycosis fungoides (MF) and Szary syndrome (SS)

    Eligibility Criteria - NCT04652960 *This information has been extracted from " www.clinicaltrials.gov"

  • 20221022 - Spiegel Jay

  • Investigator:
    Jay Spiegel
    RCname Email

    Coordinator:

    IRB: 20221022

    SDG: Lymphoma
    Disease Site(s):

    Non-Hodgkin Lymphoma

    Sponsor: Adicet Bio

    Enrolling Sites:

    Deerfield
    Gables
    Plantation
    Sylvester

    Title:

    A Phase 1 Safety and Efficacy Study of ADI-001 Anti-CD20 CAR-engineered Allogeneic Gamma Delta (d) T Cells in Adults with B Cell Malignancies

    Eligibility Criteria - NCT04735471 *This information has been extracted from " www.clinicaltrials.gov"